NEU1 and congenital rubella syndrome: However, we think that the results from this study can be explained at the cellular level by the ability of these medications to inhibit mammalian Neu-1, disrupting viral entry into the cell and the release of cytokines triggering the CRS and ARDS, as we have demonstrated in our experiments (Figure 1C–H) and a potential therapeutic target not currently recognized.